Europe issues biosimilar-friendly guidelines

Guidelines for the production of biosimilar antibody drugs in Europe released last week focused on safety rather than efficacy, setting a lower hurdle than had been feared
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: